RAPT THERAPEUTICS INC (RAPT)
US75382E1091 - Common Stock
Taking everything into account, RAPT scores 2 out of 10 in our fundamental rating. RAPT was compared to 588 industry peers in the Biotechnology industry. RAPT has a great financial health rating, but its profitability evaluates not so good. RAPT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
RAPT had negative earnings in the past year.
In the past year RAPT has reported a negative cash flow from operations.
RAPT had negative earnings in each of the past 5 years.
RAPT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RAPT has a worse Return On Assets (-67.38%) than 63.48% of its industry peers.
RAPT has a Return On Equity (-79.43%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.38% | ||
| ROE | -79.43% | ||
| ROIC | N/A |
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RAPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RAPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RAPT has more shares outstanding
Compared to 5 years ago, RAPT has more shares outstanding
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RAPT has an Altman-Z score of 1.25. This is a bad value and indicates that RAPT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.25, RAPT is in the better half of the industry, outperforming 65.53% of the companies in the same industry.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.25 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
RAPT has a Current Ratio of 7.41. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT has a better Current ratio (7.41) than 70.65% of its industry peers.
RAPT has a Quick Ratio of 7.41. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT's Quick ratio of 7.41 is fine compared to the rest of the industry. RAPT outperforms 70.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.41 | ||
| Quick Ratio | 7.41 |
3. Growth
3.1 Past
The earnings per share for RAPT have decreased strongly by -17.83% in the last year.
The Revenue for RAPT has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-17.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-25%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
RAPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.08%
EPS Next 2Y4.81%
EPS Next 3Y4.15%
EPS Next 5Y4.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
RAPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.81%
EPS Next 3Y4.15%
5. Dividend
5.1 Amount
RAPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RAPT THERAPEUTICS INC
NASDAQ:RAPT (5/3/2024, 7:14:52 PM)
After market: 8.33 0 (0%)8.33
+0.21 (+2.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap289.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.38% | ||
| ROE | -79.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.41 | ||
| Quick Ratio | 7.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-17.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-8.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y